|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...979899100101102103104105106107...110111» |
- carboplatin / Generic mfg., paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer (clinicaltrials.gov) - Jun 27, 2012
P2, N=105, Completed, Sponsor: AGO Study Group
Active, not recruiting --> Completed
- | bentamapimod (PGL5001) / Gedeon Richter
New P2a trial: PGL5001 Proof of Concept Study in Inflammatory Endometriosis (clinicaltrials.gov) - Jun 26, 2012
P2a, N=24, Recruiting, Sponsor: PregLem SA
- Trial withdrawal: Cyclooxygenase-2 Expression in Tissue Samples From Patients With a Normal Cervix, Cervical Intraepithelial Neoplasia, or Early Invasive Cervical Cancer (clinicaltrials.gov) - Jun 26, 2012
P=N/A, N=0, Withdrawn, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- Enrollment change: Cyclooxygenase-2 Expression in Tissue Samples From Patients With a Normal Cervix, Cervical Intraepithelial Neoplasia, or Early Invasive Cervical Cancer (clinicaltrials.gov) - Jun 26, 2012
P=N/A, N=0, Withdrawn, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Withdrawn N=100 --> 0
- ||||| Camtobell (belotecan) / Equisnzaroo
New P2 trial: Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial (clinicaltrials.gov) - Jun 26, 2012
P2, N=140, Recruiting, Sponsor: Chong Kun Dang Pharmaceutical
- | Yselty (linzagolix) / Kissei, Theramex, Syneos Health
New P2 trial: A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis (clinicaltrials.gov) - Jun 25, 2012
P2, N=20, Active, not recruiting, Sponsor: Kissei Pharmaceutical Co., Ltd.
- Clinical: Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer (clinicaltrials.gov) - Jun 25, 2012
P=N/A, N=400, Recruiting, Sponsor: Huazhong University of Science and Technology
- | Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
Enrollment change: Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease (clinicaltrials.gov) - Jun 24, 2012
P4, N=15, Completed, Sponsor: Mayo Clinic
N=100 --> 0 N=195 --> 15
- | Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
Trial completion: Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease (clinicaltrials.gov) - Jun 24, 2012
P4, N=15, Completed, Sponsor: Mayo Clinic
N=195 --> 15 Active, not recruiting --> Completed
- TKM-PLK1 / Arbutus
Enrollment change, Lipid Nanoparticle: TKM 080301 for Primary or Secondary Liver Cancer (clinicaltrials.gov) - Jun 22, 2012
P1, N=1, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=54 --> 1
- TKM-PLK1 / Arbutus
Trial completion, Lipid Nanoparticle: TKM 080301 for Primary or Secondary Liver Cancer (clinicaltrials.gov) - Jun 22, 2012
P1, N=1, Completed, Sponsor: National Cancer Institute (NCI)
N=54 --> 1 Recruiting --> Completed
- paclitaxel / Generic mfg.
Biomarker, Enrollment closed: Pharmacogenomics of Paclitaxel in Ovarian Cancer (clinicaltrials.gov) - Jun 21, 2012
P=N/A, N=100, Active, not recruiting, Sponsor: University of Southern Denmark
Recruiting --> Completed Recruiting --> Active, not recruiting
- | BNC105 / Bionomics
New P1/2 trial: BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients (clinicaltrials.gov) - Jun 18, 2012
P1/2, N=134, Recruiting, Sponsor: Hoosier Oncology Group
- Enrollment closed: Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis (clinicaltrials.gov) - Jun 18, 2012
P=N/A, N=50, Active, not recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Visanne (dienogest) / Mochida, Bayer
Enrollment open, HEOR: DIVA: Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=3000, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Campath (alemtuzumab) / Sanofi
Enrollment change: A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. (clinicaltrials.gov) - Jun 17, 2012
P1, N=3, Terminated, Sponsor: Ronald Buckanovich
Not yet recruiting --> Recruiting N=25 --> 3
- Enrollment open: Evaluating Coaches of Older Adults for Cancer Care and Health Behaviors (clinicaltrials.gov) - Jun 17, 2012
P=N/A, N=1100, Recruiting, Sponsor: Johns Hopkins Bloomberg School of Public Health
N=25 --> 3 Not yet recruiting --> Recruiting
- flutamide / Generic mfg.
Biomarker, Enrollment closed, IO biomarker: Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer (clinicaltrials.gov) - Jun 17, 2012
P2a, N=140, Active, not recruiting, Sponsor: University of Arizona
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||||||| New P3 trial: Safety and Efficacy Study to Treat Bacterial Vaginosis (clinicaltrials.gov) - Jun 14, 2012
P3, N=651, Completed, Sponsor: Medicis Global Service Corporation
- | RebmAb 100 / Recepta
Enrollment change: Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 14, 2012
P2, N=31, Completed, Sponsor: Recepta Biopharma
Recruiting --> Active, not recruiting N=56 --> 31
- | RebmAb 100 / Recepta
Trial completion: Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Jun 14, 2012
P2, N=31, Completed, Sponsor: Recepta Biopharma
N=56 --> 31 Active, not recruiting --> Completed
- |||||||||| Orilissa (elagolix) / AbbVie
New P3 trial: A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain (clinicaltrials.gov) - Jun 13, 2012
P3, N=875, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- |||| stenoparib (2X-121) / Allarity Therap, Oncoheroes
Enrollment open, Combination therapy, Metastases: An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jun 13, 2012
P1/2, N=198, Recruiting, Sponsor: Eisai Limited
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- | paclitaxel / Generic mfg.
Enrollment change, Metastases: S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission (clinicaltrials.gov) - Jun 12, 2012
P3, N=308, Active, not recruiting, Sponsor: Southwest Oncology Group
Active, not recruiting --> Recruiting N=450 --> 308
- dasatinib / Generic mfg.
Enrollment open: Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer (clinicaltrials.gov) - Jun 12, 2012
P0, N=20, Recruiting, Sponsor: University of Virginia
N=450 --> 308 Not yet recruiting --> Recruiting
- Tirazone (tirapazamine) / Teclison, SRI International
Trial completion, Metastases: S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer (clinicaltrials.gov) - Jun 12, 2012
P2, N=56, Completed, Sponsor: Southwest Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- carboplatin / Generic mfg., amifostine / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases: S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer (clinicaltrials.gov) - Jun 12, 2012
P2, N=57, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed: Safer Sex Intervention for Male Clients of Female Sex Workers in Tijuana, Mexico (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=400, Active, not recruiting, Sponsor: University of California, San Diego
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial termination: A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=7, Terminated, Sponsor: University of Arkansas
Recruiting --> Active, not recruiting Recruiting --> Terminated; Principal Investigator Request
- Enrollment change: A Non-Randomized Study to Evaluate Leg Lymphatic Drainage Associated With Surgical Intervention for Vulvar Cancer (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=7, Terminated, Sponsor: University of Arkansas
Recruiting --> Terminated; Principal Investigator Request N=10 --> 7
- ||||| stenoparib (2X-121) / Allarity Therap, Oncoheroes
New P1/2 trial, Combination therapy, Metastases: An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jun 11, 2012
P1/2, N=198, Recruiting, Sponsor: Eisai Limited
- Viracept (nelfinavir) / ViiV Healthcare, Roche
Enrollment open, Metastases: Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer (clinicaltrials.gov) - Jun 11, 2012
P1, N=24, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
N=10 --> 7 Not yet recruiting --> Recruiting
- ||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Lucrin Depot (clinicaltrials.gov) - Jun 11, 2012
P=N/A, N=391, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | perifosine (D21266) / AEterna Zentaris
Biomarker, Trial completion: Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer (clinicaltrials.gov) - Jun 11, 2012
P1, N=22, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Cvac (cancer vaccine MUC-1) / Sydys Corp
New P2 trial: Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study (clinicaltrials.gov) - Jun 10, 2012
P2, N=9, Active, not recruiting, Sponsor: Prima BioMed Ltd
- cisplatin / Generic mfg., paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial withdrawal, Metastases: S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer (clinicaltrials.gov) - Jun 10, 2012
P3, N=0, Withdrawn, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Withdrawn
- | Cynviloq (paclitaxel polymeric micelle formulation) / Sorrento, Samyang Group, ImmunityBio
Trial completion, Combination therapy, Metastases: Determine MTD, Evaluate Efficacy and Safety of Genexol (clinicaltrials.gov) - Jun 10, 2012
P1, N=18, Completed, Sponsor: Samyang Biopharmaceuticals Corporation
Active, not recruiting --> Withdrawn Active, not recruiting --> Completed
- | pegylated liposomal doxorubicin / Generic mfg., carboplatin / Generic mfg.
Trial completion: S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - Jun 10, 2012
P3, N=61, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Trial initiation date: EMR200061-506: A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique (clinicaltrials.gov) - Jun 7, 2012
P3, N=208, Recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed Initiation date: Jan 2012 --> May 2012
- |||||| Enrollment open: EMR200061-506: A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique (clinicaltrials.gov) - Jun 7, 2012
P3, N=208, Recruiting, Sponsor: Merck KGaA
Initiation date: Jan 2012 --> May 2012 Not yet recruiting --> Recruiting
- Enrollment change: Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer (clinicaltrials.gov) - Jun 7, 2012
P=N/A, N=0, Withdrawn, Sponsor: Northwestern University
Not yet recruiting --> Recruiting N=200 --> 0
- |||||||||| Zorbtive (somatropin) / EMD Serono
New P2/3 trial: Growth Hormone in Poor Responders to IVF Trial (clinicaltrials.gov) - Jun 7, 2012
P2/3, N=60, Recruiting, Sponsor: Pacific Centre for Reproductive Medicine
- Clinical: Blood Vessel Function in Adolescents and Women With Polycystic Ovary Syndrome (clinicaltrials.gov) - Jun 6, 2012
P=N/A, N=60, Recruiting, Sponsor: Virginia Commonwealth University
- ||| Trial completion: Eeva™ System Study: Noninvasive Recording and Visualization of Individual Embryos Cultured to Blastocyst Stage (clinicaltrials.gov) - Jun 6, 2012
P=N/A, N=160, Completed, Sponsor: Auxogyn, Inc.
N=200 --> 0 Active, not recruiting --> Completed
- cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial termination: Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction (clinicaltrials.gov) - Jun 6, 2012
P1/2, N=1, Terminated, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Recruiting --> Terminated; Slow accrual
- cisplatin / Generic mfg., paclitaxel / Generic mfg.
Enrollment change: Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction (clinicaltrials.gov) - Jun 6, 2012
P1/2, N=1, Terminated, Sponsor: University Health Network, Toronto
Recruiting --> Terminated; Slow accrual N=15 --> 1
- Enrollment change: Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers (clinicaltrials.gov) - Jun 6, 2012
P=N/A, N=15, Completed, Sponsor: Lawson Health Research Institute
N=15 --> 1 N=100 --> 15
- Trial completion: Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers (clinicaltrials.gov) - Jun 6, 2012
P=N/A, N=15, Completed, Sponsor: Lawson Health Research Institute
N=100 --> 15 Recruiting --> Completed
- |||| Enrollment open: Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] in Men Who Have Sex With Men [MSM] (clinicaltrials.gov) - Jun 5, 2012
P4, N=1000, Recruiting, Sponsor: University of California, San Francisco
Recruiting --> Completed Not yet recruiting --> Recruiting
- | buparlisib (AN2025) / Novartis, Adlai Nortye
New P2 trial, Metastases: Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer (clinicaltrials.gov) - Jun 5, 2012
P2, N=27, Not yet recruiting, Sponsor: Novartis Pharmaceuticals